T-cells from common cold can help protect against Covid-19
The authors of a new study say that the internal proteins of the SARS-CoV-2 virus that are targeted by T-cells could offer an alternative target for vaccine makers
10 January 2022 - 13:11
by Alistair Smout
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
T-cells are believed to play a vital role in providing protection from Covid-19. Picture: 123RF/MARCTRAN
London — High levels of T-cells from common cold coronaviruses can provide protection against Covid-19, an Imperial College London study published on Monday has found, which could inform approaches for second-generation vaccines.
Immunity against Covid-19 is a complex picture, and while there is evidence of waning antibody levels six months after vaccination, T-cells are also believed to play a vital role in providing protection.
The study, which began in September 2020, looked at levels of cross-reactive T-cells generated by previous common colds in 52 household contacts of positive Covid-19 cases shortly after exposure, to see if they went on to develop infection.
It found that the 26 who did not develop infection had significantly higher levels of those T-cells than people who did get infected. Imperial did not say how long protection from the T-cells would last.
“We found that high levels of pre-existing T cells, created by the body when infected with other human coronaviruses like the common cold, can protect against Covid-19 infection,” study author Dr Rhia Kundu said.
The authors of the study, published in Nature Communications, said that the internal proteins of the SARS-CoV-2 virus that are targeted by the T-cells could offer an alternative target for vaccine makers.
Current Covid-19 vaccines target the spike protein, which mutates regularly, creating variants such as Omicron, which lessen the efficacy of vaccines against symptomatic infection.
“In contrast, the internal proteins targeted by the protective T-cells we identified mutate much less,” Prof Ajit Lalvani, co-author of the study, said.
“Consequently, they are highly conserved between the various SARS-CoV-2 variants, including Omicron. New vaccines that include these conserved, internal proteins would therefore induce broadly protective T-cell responses that should protect against current and future SARS-CoV-2 variants.”
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
T-cells from common cold can help protect against Covid-19
The authors of a new study say that the internal proteins of the SARS-CoV-2 virus that are targeted by T-cells could offer an alternative target for vaccine makers
London — High levels of T-cells from common cold coronaviruses can provide protection against Covid-19, an Imperial College London study published on Monday has found, which could inform approaches for second-generation vaccines.
Immunity against Covid-19 is a complex picture, and while there is evidence of waning antibody levels six months after vaccination, T-cells are also believed to play a vital role in providing protection.
The study, which began in September 2020, looked at levels of cross-reactive T-cells generated by previous common colds in 52 household contacts of positive Covid-19 cases shortly after exposure, to see if they went on to develop infection.
It found that the 26 who did not develop infection had significantly higher levels of those T-cells than people who did get infected. Imperial did not say how long protection from the T-cells would last.
“We found that high levels of pre-existing T cells, created by the body when infected with other human coronaviruses like the common cold, can protect against Covid-19 infection,” study author Dr Rhia Kundu said.
The authors of the study, published in Nature Communications, said that the internal proteins of the SARS-CoV-2 virus that are targeted by the T-cells could offer an alternative target for vaccine makers.
Current Covid-19 vaccines target the spike protein, which mutates regularly, creating variants such as Omicron, which lessen the efficacy of vaccines against symptomatic infection.
“In contrast, the internal proteins targeted by the protective T-cells we identified mutate much less,” Prof Ajit Lalvani, co-author of the study, said.
“Consequently, they are highly conserved between the various SARS-CoV-2 variants, including Omicron. New vaccines that include these conserved, internal proteins would therefore induce broadly protective T-cell responses that should protect against current and future SARS-CoV-2 variants.”
Reuters
Cyprus lab finds Covid-19 infections that mix up Delta and Omicron
Rapid spreading of Omicron puts Europe’s healthcare under pressure
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Health department gears up for booster shot bustle
Sinopharm develops a stronger booster against Omicron
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.